Navigation Links
InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Date:1/4/2012

BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012.  A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day.  InterMune also plans to report additional efficacy and survival data from the ongoing RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).  The company will review its plans to gain reimbursement for Esbriet across Europe and an expert in German drug reimbursement law will answer questions on the call.  Additionally, the company will update its expense guidance for 2011 and will provide forward-looking expense guidance for the full year 2012.  

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495.  To access the live webcast of the call, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call and will remain available until the company's next earnings call.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  The registration deadline has ... Financial Officers (ABFO) 2013 National Conference, the premier conference ... May 28-31 at the Hilton San Diego Bayfront. ... this year,s conference and want to make sure as ... said Brandi Roberts , Chief Financial ...
(Date:5/16/2013)... FL (PRWEB) May 16, 2013 As the ... to showcase their favorite Spring looks. While most make a ... season. Unfortunately, many women find the warmer weather mixes makeup ... women cope with the onset of acne during warmer months, ... from female acne treatment users the best ways to deter ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... Analysis: Therapeutic Proteins – Biosimilars, Biobetters ...   Product ... The new Competitive Intelligence Report Therapeutic ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – The ... and Future Opportunities (13-004) , With barriers to ... cells market continues to increase. In this study, BioInformatics ... how satisfied scientists are with commercially available primary cells, ... ,  , Additionally, terminally differentiated cells can be ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Mich., Jan. 23, 2012  A recent Van Andel Research Institute ... the molecular structure and function of an essential plant hormone ... and might ultimately lead to the development of new drugs ... builds on earlier work by the same team of investigators ...
... Jan. 23, 2012 Aethlon Medical, Inc. ... therapeutic filtration devices to address infectious disease, cancer ... has established an Extracorporeal Therapy Scientific Advisory Board ... and other therapies developed from the Aethlon ADAPT™ ...
... NEW YORK, Jan. 23, 2012   NeoStem, Inc. (NYSE ... international biopharmaceutical company with a focus on cell-based therapeutic development, ... for its PreSERVE Phase 2 clinical trial for ... infarction patients, and the President of its subsidiary, Progenitor ...
Cached Biology Technology:Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 2Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 4
(Date:5/16/2013)... to a fast food restaurant had a higher body ... from fast food, according to researchers at The University ... was particularly strong among those with a lower income. ... American Journal of Public Health indicates higher ... restaurant, and among lower-income African-Americans, the density, or number, ...
(Date:5/16/2013)... the cellular layer lining the body,s blood vessels, ... nanometers in thickness, this super-tenuous structure routinely withstands ... to create a unique and highly dynamic barrier ... from the body,s circulatory system. , It,s also ... be physically breached to enable immune cells ...
(Date:5/16/2013)... has discovered an ancient extinct creature with ,scissor hand-like, ... honour of his favourite movie star. , The ... (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ancestor ... Johnny Depp for his starring role as Edward Scissorhands ... an unfinished creation, who has scissors for hands. ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Actor Johnny Depp immortalized in ancient fossil find 2
... long and very cold but the winter of 2009-2010 ... and the re-introduced wild Przewalski,s horse population crashed dramatically. ... Veterinary Medicine, Vienna have used spatially explicit loss statistics, ... into the effect of a catastrophic climate event on ...
... New research has found that elderly people with higher ... their blood had better performance on mental acuity tests and ... while "junk food" diets produced just the opposite result. ... specifically measure a wide range of blood nutrient levels instead ...
... research suggests that China,s impressive feat of cutting Beijing,s pollution ... some help from Mother Nature. Rain just at the beginning ... the effort needed to clean up the skies, scientists found. ... widely implemented than in 2008 if pollution levels are to ...
Cached Biology News:Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 2Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 3Diet, nutrient levels linked to cognitive ability, brain shrinkage 2Weather deserves medal for clean air during 2008 Olympics 2
Request Info...
... in two product models - the 5000AT+ and ... that the 6000AT+ includes a membrane desolvation unit ... improved detection limits and reduced oxides. The Ultrasonic ... elements by 10-40 times. Note that with ICP-MS ...
... For potent inhibition of RNase A-type ... a protein of nonhuman origin that binds ... (e.g., RNase A, B, and C). It ... H, U1, U2, or CL3. QIAGEN RNase ...
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
Biology Products: